ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1891

Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial

Walter P Maksymowych1, Louis Bessette2, Robert G Lambert3, Amanda Carapellucci4 and Tom Appleton5, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 3University of Alberta, Edmonton, AB, Canada, 4CARE Arthritis LTD, Edmonton, AB, Canada, 5The University of Western Ontario, London, ON, Canada

Meeting: ACR Convergence 2022

Keywords: Anti-TNF Drugs, clinical trial, Inflammation, Osteoarthritis, pain

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Osteoarthritis – Clinical Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Recent RCTs demonstrated that TNFα inhibition has no effect on pain and MRI-detected synovitis or bone marrow lesions in patients with erosive hand OA. However, the progression of bone erosions was reduced in a subgroup of patients with more clinically swollen distal interphalangeal joints in one RCT. Consequently, it remains possible that TNFα inhibition may have beneficial effects in specific subgroups of patients with a high inflammatory component. We aimed to evaluate the efficacy and safety of a TNFα inhibitor, adalimumab (ADA), in a proof-of-concept study in patients with inflammatory OA of the knee.

Methods: OKINADA was a 52-week, randomized, double-blind, placebo-controlled, parallel-group study done at 11 sites in Canada (NCT02471118). Eligible participants were adults with a diagnosis of OA of the index knee and classified according to American College of Rheumatology criteria, including radiological evidence of OA (Kellgren-Lawrence grades 2 or 3), with clinical signs of knee effusion. Subjects had persistent knee pain of ≥ one month duration with a pain score of ≥ 4 (0-10 NRS) in the index knee at screening and baseline despite conventional treatment with maximum tolerated acetaminophen and/or non-steroidal anti-inflammatory drug. Patients were randomly assigned (1:1) to receive subcutaneous 40 mg ADA every 2 weeks or placebo (PBO) to week 16. All patients then received open label ADA to week 32. Primary endpoint was the Outcome Measures in Rheumatology and Osteoarthritis Research Society International set of responder criteria (OMERACT-OARSI) at week 16. Secondary endpoints included: the Knee Injury and Osteoarthritis Outcome Score (KOOS) for the domains of pain, activities of daily living (ADL), OA symptoms, sport and recreation function (SRF), and knee-related quality of life (QoL), patient global assessment of disease status (PGAD), investigator global assessment of disease status (IGAD), and expanded Target Joint Assessment (TJA) score.

Results: A total of 58 patients were randomized (28 to PBO, 30 to ADA) and patients were well-matched for baseline characteristics (Table). The primary endpoint was not met: OMERACT-OARSI combined (ADA: 9 [30.0%] vs PBO: 7 [25%], p=0.90) (Figure 1). For KOOS pain, ≥20% improvement was noted in 11 (36.7%) ADA vs 7 (25.0%) PBO patients (p=0.50), and ≥50% improvement in 5 (16.7%) ADA vs 6 (21.4%) PBO patients (p=0.90). There were no significant treatment-group differences in baseline to 16-week change in continuous secondary endpoints (KOOS ADL-QoL-Symptoms-SRF, PGAD, IGAD, TJA, physical assessment of the target knee) or in lab markers (ESR, CRP) (Figure 2). OMERACT-OARSI response increased to 53.3% (ITT) at week 32 in the group randomized to ADA. There were 9 withdrawals (4 ADA, 5 PBO) to week 16 and 3 withdrawals between weeks 16-32 but no new safety signals were identified and there were no serious adverse events.

Conclusion: Although the treatment was safe, short-term treatment with anti-TNFα therapy does not appear to provide clinically meaningful improvements in OA symptoms though it remains possible that longer duration of treatment could be beneficial. Analyses of structural endpoints will be reported when results are available.

Supporting image 1

Table. Baseline characteristics of patients randomized 1:1 to either adalimumab or placebo.

Supporting image 2

Figure 1. OMERACT-OARSI responses in patients with inflammatory knee osteoarthritis randomized 1:1 to adalimumab or placebo to week 16 and then all patients receiving open label adalimumab from 16_32 weeks. NRI non-responder imputation data AO as observed data

Supporting image 3

Figure 2. Change in KOOS Pain and Function in patients with knee osteoarthritis randomized 1:1 to adalimumab or placebo to 16 weeks and then all patients receiving open label adalimumab from 16_32 weeks.


Disclosures: W. Maksymowych, AbbVie, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, CARE Arthritis Limited; L. Bessette, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi-Genzyme, UCB, Gilead, Merck/MSD, Organon, Roche; R. Lambert, Calyx, CARE Arthritis, Image Analysis Group; A. Carapellucci, None; T. Appleton, AbbVie/Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb(BMS), Celgene, Fresenius Kabi, Gilead, Janssen, Merck/MSD, Novartis, Organon, Pfizer, Roche, UCB, Sanofi-Genzyme.

To cite this abstract in AMA style:

Maksymowych W, Bessette L, Lambert R, Carapellucci A, Appleton T. Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/osteoarthritis-of-the-knee-inflammation-and-the-effect-of-adalimumab-a-randomized-placebo-controlled-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoarthritis-of-the-knee-inflammation-and-the-effect-of-adalimumab-a-randomized-placebo-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology